PH12019550238A1 - Human antibodies to bet v 1 and methods of use thereof - Google Patents

Human antibodies to bet v 1 and methods of use thereof

Info

Publication number
PH12019550238A1
PH12019550238A1 PH12019550238A PH12019550238A PH12019550238A1 PH 12019550238 A1 PH12019550238 A1 PH 12019550238A1 PH 12019550238 A PH12019550238 A PH 12019550238A PH 12019550238 A PH12019550238 A PH 12019550238A PH 12019550238 A1 PH12019550238 A1 PH 12019550238A1
Authority
PH
Philippines
Prior art keywords
antibodies
bet
fagales
allergens
methods
Prior art date
Application number
PH12019550238A
Other languages
English (en)
Inventor
Jamie M Orengo
Andrew J Murphy
Ashok T Badithe
Vishal Kamat
Yashu Liu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PH12019550238A1 publication Critical patent/PH12019550238A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH12019550238A 2017-06-01 2019-11-14 Human antibodies to bet v 1 and methods of use thereof PH12019550238A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762513872P 2017-06-01 2017-06-01
US201762571696P 2017-10-12 2017-10-12
US201862662165P 2018-04-24 2018-04-24
PCT/US2018/035366 WO2018222854A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Publications (1)

Publication Number Publication Date
PH12019550238A1 true PH12019550238A1 (en) 2020-10-19

Family

ID=62705709

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019550238A PH12019550238A1 (en) 2017-06-01 2019-11-14 Human antibodies to bet v 1 and methods of use thereof

Country Status (17)

Country Link
US (3) US10793624B2 (https=)
EP (1) EP3630814A1 (https=)
JP (3) JP6963036B2 (https=)
KR (3) KR102329175B1 (https=)
CN (1) CN110997713B (https=)
AU (2) AU2018275657B2 (https=)
BR (1) BR112019025150B1 (https=)
CA (1) CA3063588A1 (https=)
CL (3) CL2019003508A1 (https=)
CO (1) CO2019013196A2 (https=)
IL (2) IL270894B2 (https=)
MX (2) MX2019014430A (https=)
MY (1) MY198270A (https=)
NZ (1) NZ759513A (https=)
PH (1) PH12019550238A1 (https=)
WO (1) WO2018222854A1 (https=)
ZA (1) ZA201907513B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635527B (zh) 2015-03-10 2021-04-23 里珍纳龙药品有限公司 无菌刺穿系统和方法
IL308643B2 (en) 2017-05-05 2025-02-01 Regeneron Pharma Auto-injector
IL270894B2 (en) * 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
AU2021300129A1 (en) 2020-07-01 2022-12-08 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies
CN113041271B (zh) * 2021-04-14 2022-12-27 浙江养生堂天然药物研究所有限公司 具有预防和抗过敏功效的组合物
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
US20230174632A1 (en) * 2021-12-08 2023-06-08 IgGenix, Inc. Combinations for allergy therapy
EP4688165A1 (en) 2023-03-31 2026-02-11 ALK-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
WO2024251358A1 (en) * 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof
CN121548440A (zh) 2023-06-16 2026-02-17 里珍纳龙药品有限公司 医疗装置包装及相关方法
US20250011403A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-sp17 antibodies and other sp17 binding proteins
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025117894A2 (en) * 2023-11-29 2025-06-05 Medicovestor, Inc. Dimeric immunoconjugates for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US20250263471A1 (en) 2024-01-30 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5411594A (en) 1992-10-27 1994-05-24 Biomay Produktions- Und Handelsgesellschaft M.B.H. Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) * 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) * 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
US10935554B2 (en) * 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
IL270894B2 (en) 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
AU2021300129A1 (en) * 2020-07-01 2022-12-08 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies

Also Published As

Publication number Publication date
CO2019013196A2 (es) 2020-01-17
KR102878718B1 (ko) 2025-10-31
JP6963036B2 (ja) 2021-11-05
JP2020523004A (ja) 2020-08-06
KR20200012892A (ko) 2020-02-05
ZA201907513B (en) 2022-04-28
JP2021112207A (ja) 2021-08-05
AU2022200272A1 (en) 2022-02-10
CN110997713A (zh) 2020-04-10
CA3063588A1 (en) 2018-12-06
AU2022200272B2 (en) 2024-10-03
KR102674000B1 (ko) 2024-06-11
IL298034B2 (en) 2024-05-01
CL2021002851A1 (es) 2022-08-19
AU2018275657A1 (en) 2019-12-19
KR20210143327A (ko) 2021-11-26
CL2019003508A1 (es) 2020-06-19
IL270894A (en) 2020-01-30
MX2023000390A (es) 2023-02-13
CL2021002850A1 (es) 2022-06-24
US11767358B2 (en) 2023-09-26
NZ782911A (en) 2025-08-29
JP7162097B2 (ja) 2022-10-27
US20210054056A1 (en) 2021-02-25
KR20240096746A (ko) 2024-06-26
JP7458453B2 (ja) 2024-03-29
BR112019025150A2 (pt) 2020-06-23
CN110997713B (zh) 2024-01-02
JP2022174238A (ja) 2022-11-22
KR102329175B1 (ko) 2021-11-19
IL270894B2 (en) 2023-04-01
MX2019014430A (es) 2020-07-14
US20180346555A1 (en) 2018-12-06
EP3630814A1 (en) 2020-04-08
BR112019025150B1 (pt) 2022-11-08
IL298034B1 (en) 2024-01-01
WO2018222854A1 (en) 2018-12-06
IL270894B (en) 2022-12-01
MY198270A (en) 2023-08-18
NZ759513A (en) 2022-01-28
US20240083986A1 (en) 2024-03-14
US10793624B2 (en) 2020-10-06
IL298034A (en) 2023-01-01
AU2018275657B2 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
PH12019550238A1 (en) Human antibodies to bet v 1 and methods of use thereof
ZA202202846B (en) Human antibodies to fel d1 and methods of use thereof
MY146664A (en) Antibodies against human il-22 and uses therefor
MY171180A (en) Anti-hla-b*27 antibodies and uses thereof
SA520420301B1 (ar) مستقبلات خيمرية لشبيه الدلتا 3 وطرق استخدامها
GEP20237480B (en) Antibodies against signal-regulatory protein alpha and methods of use
WO2019118902A3 (en) Compositions and methods for inhibiting t cell exhaustion
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
WO2016142783A3 (en) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
EP2796469A3 (en) Novel compositions and methods for treating ige-mediated disorders
HK1250238A1 (zh) 抗angptl8抗体及其用途
WO2007100643A3 (en) Methods of using antibodies against human il-22
WO2017136820A3 (en) Fabs-in-tandem immunoglobulin and uses thereof
WO2015069922A3 (en) Alk antibodies, conjugates, and chimeric antigen receptors, and their use
WO2006007529A3 (en) Immunosuppressive exosomes
NZ596022A (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
WO2016004389A3 (en) Monovalent binding proteins
SG196839A1 (en) Antibodies against fcrn and use thereof
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
WO2014165028A8 (en) Antibodies specific to a novel epitope on cemx of human membrane-bound ige and uses thereof in treating ige-mediated diseases
EA201992651A1 (ru) АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2015077434A3 (en) Pan pollen immunogens and methods and uses thereof for immune response modulation
WO2018005904A3 (en) Methods and compositions for pdgf-cc inhibition
TH97938A (th) แอนติบอดีต่อต้าน il-22 ของมนุษย์และวิธีการใช้สำหรับการนั้น